QuantuMDx Group has entered a collaboration deal with in-vitro diagnostic solution provider Sansure Biotech to expedite the commercialisation of the Q-POC platform and its assays in China.

The financial terms of the deal were not disclosed by the companies.

Under the agreement terms, the companies will collaborate on global research and development, production, and commercialisation to bring a complete array of innovative molecular diagnostic tests to the Q-POC platform.

The Q-POC platform is a quick multiplex polymerase chain reaction (PCR) diagnostic system that provides accurate results in about 30 minutes at the point of need.

The portable platform compresses a complete molecular diagnostic laboratory into one system.

QuantuMDx and Sansure Biotech will team up to expedite the development of new assays for the platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

QuantuMDx CEO Jonathan O’Halloran said: “This cooperation agreement will now enable both companies to explore and leverage reagent, components of the Q-POC instrument and cassette assays for cost down opportunities and scalability in China, with an expectation to reduce our cost of goods.

“Coupled with Sansure’s expert knowledge of commercialising molecular diagnostics in the region, I believe we are well placed to build a strong presence in China and other territories in this important market.”

According to the terms of the deal, Sansure Biotech will have exclusive rights to commercialise the Q-POC platform in China.

QuantuMDx will receive royalty payments and licensing in exchange. It will also have the exclusive rights to sell the assays developed on the platform outside the country.

Last November, QuantuMDx secured £15m in funding from Hong Kong-based venture capital firm Vita Spring IVD Fund.